Usefulness of Inhaled Sedation in Patients With Severe ARDS Due to COVID-19

REFERENCES

1. 1.↵
   1. Guy GP Jr..,
   2. Zhang K,
   3. Bohm MK,
   4. Losby J,
   5. Lewis B,
   6. Young R,
   7. et al

   . Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66(26):697-704.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Dubey MJ,
   2. Ghosh R,
   3. Chatterjee S,
   4. Biswas P,
   5. Chatterjee S,
   6. Dubey S

   . COVID-19 and addiction. Diabetes Metab Syndr 2020;14(5):817-823.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Velikova T,
   2. Georgiev T

   . SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int 2021;41(3):509-518.

   OpenUrlCrossRefPubMed
4. 4.
   1. Ahn D-G,
   2. Shin H-J,
   3. Kim M-H,
   4. Lee S,
   5. Kim H-S,
   6. Myoung J,
   7. et al

   . Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 2020;30(3):313-324.

   OpenUrlPubMed
5. 5.
   1. Meyer NJ,
   2. Gattinoni L,
   3. Calfee CS

   . Acute respiratory distress syndrome. Lancet 2021;398(10300):622-637.

   OpenUrlPubMed
6. 6.↵
   1. Wang F,
   2. Kream RM,
   3. Stefano GB

   . Long-term respiratory and neurological sequelae of COVID-19. Med Sci Monit 2020;26:e928996.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Huppert LA,
   2. Matthay MA,
   3. Ware LB

   . Pathogenesis of acute respiratory distress syndrome. Semin Respir Crit Care Med 2019;40(1):31-39.

   OpenUrlCrossRefPubMed
8. 8.
   1. Ranieri VM,
   2. Rubenfeld GD,
   3. Thompson BT,
   4. Ferguson ND,
   5. Caldwell E,
   6. Fan E,
   7. et al

   ; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307(23):2526-2533.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.
   1. Gibson PG,
   2. Qin L,
   3. Puah SH

   . COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust 2020;213(2):54-56.e1.

   OpenUrlCrossRef
10. 10.
    1. Navas-Blanco JR,
    2. Dudaryk R

    . Management of respiratory distress syndrome due to COVID-19 infection. BMC Anesthesiol 2020;20(1):177.

    OpenUrlPubMed
11. 11.
    1. Gautret P,
    2. Million M,
    3. Jarrot PA,
    4. Camoin-Jau L,
    5. Colson P,
    6. Fenollar F,
    7. et al

    . Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol 2020;16(12):1159-1184.

    OpenUrl
12. 12.
    1. Pfortmueller CA,
    2. Spinetti T,
    3. Urman RD,
    4. Luedi MM,
    5. Schefold JC

    . COVID-19–associated acute respiratory distress syndrome (CARDS): current knowledge on pathophysiology and ICU treatment - A narrative review. Best Pract Res Clin Anaesthesiol 2021;35(3):351-368.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Chanques G,
    2. Constantin JM,
    3. Devlin JW,
    4. Ely EW,
    5. Fraser GL,
    6. Gélinas C,
    7. et al

    . Analgesia and sedation in patients with ARDS. Intensive Care Med 2020;46(12):2342-2356.

    OpenUrlPubMed
14. 14.↵
    1. Pearson SD,
    2. Patel BK

    . Evolving targets for sedation during mechanical ventilation. Curr Opin Crit Care 2020;26(1):47-52.

    OpenUrl
15. 15.↵
    1. Celis-Rodríguez E,
    2. Birchenall C,
    3. de la Cal M,
    4. Castorena Arellano G,
    5. Hernández A,
    6. Ceraso D,
    7. et al

    ; Federación Panamericana e Ibérica de Sociedades de Medicina Crítica y Terapia Intensiva. Clinical practice guidelines for evidence-based management of sedoanalgesia in critically ill adult patients. Med Intensiva 2013;37(8):519-574.

    OpenUrl
16. 16.↵
    1. Celis-Rodríguez E,
    2. Díaz Cortés JC,
    3. Cárdenas Bolívar YR,
    4. Carrizosa González JA,
    5. Pinilla DI,
    6. Ferrer Záccaro LE,
    7. et al

    . Evidence-based clinical practice guidelines for the management of sedoanalgesia and delirium in critically ill adult patients. Med Intensiva (Engl Ed) 2020;44(3):171-184.

    OpenUrl
17. 17.↵
    1. Chisholm-Burns MA,
    2. Spivey CA,
    3. Sherwin E,
    4. Wheeler J,
    5. Hohmeier K

    . The opioid crisis: origins, trends, policies, and the roles of pharmacists. Am J Health Syst Pharm 2019;76(7):424-435.

    OpenUrlPubMed
18. 18.
    1. Shipton EA,
    2. Shipton EE,
    3. Shipton AJ

    . A review of the opioid epidemic: what do we do about it? Pain Ther 2018;7(1):23-36.

    OpenUrlPubMed
19. 19.
    1. Durkin E

    . US drug overdose deaths rose to record 72,000 last year. The Guardian: August 16, 2018. Available at: https://www.theguardian.com/us-news/2018/aug/16/us-drug-overdose-deaths-opioids-fentanyl-cdc.
20. 20.↵
    1. Mallet J,
    2. Dubertret C,
    3. Le Strat Y

    . Addictions in the COVID-19 era: current evidence, future perspectives a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110070.

    OpenUrlPubMed
21. 21.↵
    1. Palamim CVC,
    2. Boschiero MN,
    3. Faria AG,
    4. Valencise FE,
    5. Marson FAL

    . Opioids in COVID-19: two sides of a coin. Front Pharmacol 2021;12:758637.

    OpenUrl
22. 22.↵
    1. Hraiech S,
    2. Yoshida T,
    3. Annane D,
    4. Duggal A,
    5. Fanelli V,
    6. Gacouin A,
    7. et al

    . Myorelaxants in ARDS patients. Intensive Care Med 2020;46(12):2357-2372.

    OpenUrl
23. 23.↵
    1. Yoshida T,
    2. Nakahashi S,
    3. Nakamura MAM,
    4. Koyama Y,
    5. Roldan R,
    6. Torsani V,
    7. et al

    . Volume controlled ventilation does not prevent injurious inflation during spontaneous effort. Am J Respir Crit Care Med 2017;196(5):590-601.

    OpenUrl
24. 24.↵
    1. Guervilly C,
    2. Bisbal M,
    3. Forel JM,
    4. Mechati M,
    5. Lehingue S,
    6. Bourenne J,
    7. et al

    . Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med 2017;43(3):408-418.

    OpenUrlPubMed
25. 25.↵
    1. Testelmans D,
    2. Maes K,
    3. Wouters P,
    4. Powers SK,
    5. Decramer M,
    6. Gayan-Ramirez G

    . Infusions of rocuronium and cisatracurium exert different effects on rat diaphragm function. Intensive Care Med 2007;33(5):872-879.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Papazian L,
    2. Forel JM,
    3. Gacouin A,
    4. Penot-Ragon C,
    5. Perrin G,
    6. Loundou A,
    7. et al

    ; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363(12):1107-1116.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Pollard CA,
    2. Morran MP,
    3. Nestor-Kalinoski AL

    . The COVID-19 pandemic: a global health crisis. Physiol Genomics 2020;52(11):549-557.

    OpenUrlPubMed
28. 28.
    1. Farrell R,
    2. Oomen G,
    3. Carey P

    . A technical review of the history, development, and performance of the anesthetic conserving device “AnaConDa” for delivering volatile anesthetic in intensive and post-operative critical care. J Clin Monit Comput 2018;32(4):595-604.

    OpenUrl
29. 29.↵
    1. Laferriere-Langlois P,
    2. d’Aragon AF,
    3. Manzanares W

    . Halogenated volatile anesthetics in the intensive care unit: current knowledge on an upcoming practice. Minerva Anestesiol 2017;83(7):737-748.

    OpenUrl
30. 30.↵
    1. Mallah SI,
    2. Ghorab OK,
    3. Al-Salmi S,
    4. Abdellatif OS,
    5. Tharmaratnam T,
    6. Iskandar MA,
    7. et al

    . COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob 2021;20(1):35.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Flinspach AN,
    2. Zacharowski K,
    3. Ioanna D,
    4. Adam EH

    . Volatile isoflurane in critically ill coronavirus disease 2019 patients-a case series and systematic review. Crit Care Explor 2020;2(10):e0256.

    OpenUrlPubMed
32. 32.↵
    1. Wolf A,
    2. Mörgeli R,
    3. Müller A,
    4. Weiss B,
    5. Spies C

    . Delirium, analgesia, and sedation in intensive care medicine: development of a protocol-based management approach. Med Klin Intensivmed Notfmed 2017;112(1):65-74.

    OpenUrl
33. 33.↵
    Sanitarios. Agencia Francesa para la Seguridad de los Productos Sanitarios. Available at: https://www.emergobyul.com/resources/asnm-agencia-francesa-seguridad-productos-sanitarios. Noviembre de 2021.
34. 34.↵
    1. Landoni G,
    2. Pasin L,
    3. Cabrini L,
    4. Scandroglio AM,
    5. Baiardo Redaelli M,
    6. Votta CD,
    7. et al

    . Volatile agents in medical and surgical intensive care units: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2016;30(4):1005-1014.

    OpenUrl
35. 35.↵
    1. Delgado-Herrera L,
    2. Ostroff RD,
    3. Rogers SA

    . Sevoflurance: approaching the ideal inhalational anesthetic. A pharmacologic, pharmacoeconomic, and clinical review. CNS Drug Rev 2001;7(1):48-120.

    OpenUrlPubMed
36. 36.↵
    1. Meiser A,
    2. Volk T,
    3. Wallenborn J,
    4. Guenther U,
    5. Becher T,
    6. Bracht H,
    7. et al

    ; Sedaconda study group. Inhaled isoflurane via the anesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomized controlled, non-inferiority trial. Lancet Respir Med 2021;9(11):1231-1240.

    OpenUrl
37. 37.↵
    1. Edalatkhah A,
    2. Kazemi MR,
    3. Samadi Khorshidi F,
    4. Akhoundimeybodi Z,
    5. Seyedhosseini SM,
    6. Rostami S,
    7. et al

    . Comparison of the effects of etomidate, ketamine, sodium thiopental, and midazolam on the mortality of patients with COVID-19 requiring intubation. Med J Islam Repub Iran 2021;35:49.

    OpenUrl
38. 38.↵
    1. Krewulak KD,
    2. Stelfox HT,
    3. Ely EW,
    4. Fiest KM

    . Risk factors and outcomes among delirium subtypes in adult ICUs: a systematic review. J Crit Care 2020;56:257-264.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Smeets TJL,
    2. Valkenburg AJ,
    3. van der Jagt M,
    4. Koch BCP,
    5. Endeman H,
    6. Gommers D,
    7. et al

    . Hyperinflammation reduces midazolam metabolism in critically ill adults with COVID-19. Clin Pharmacokinet 2022;61(7):973-983.

    OpenUrl
40. 40.↵
    1. Turner GB,
    2. O’Rourke D,
    3. Scott GO,
    4. Beringer TR

    . Fatal hepatotoxicity after re-exposure to isoflurane: a case report and review of the literature. Eur J Gastroenterol Hepatol 2000;12(8):955-959.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Stollings LM,
    2. Jia LJ,
    3. Tang P,
    4. Dou H,
    5. Lu B,
    6. Xu Y

    . Immune modulation by volatile anesthetics. Anesthesiology 2016;125(2):399-411.

    OpenUrlCrossRefPubMed